Long-Term Outcomes Of Heart Transplantation For Severe Cardiomegaly
Published on: April 29, 2025
long-term outcomes of heart transplantation for severe cardiomegaly featured image
  • Article author photo

    Michael Collins

    Master of Science - MS, Oncology, University of Nottingham

Overview

Cardiomegaly, otherwise known as heart enlargement, is defined by the heart exceeding 50% of the width of the chest during an X-ray. Most of the time, it is a result of an underlying health condition, such as heart valve disease, coronary artery disease, or myocarditis.1 Over time, cardiomegaly weakens the heart, worsening its ability to pump blood properly. This acts as a precursor to heart failure. 

Heart failure is a chronic condition that gradually causes the decline of its structure and function. When heart failure reaches its end stage, and other treatments, such as beta-blockers or angiotensin-converting enzyme (ACE) inhibitors, do not improve the patient’s condition, a heart transplant is considered a last-resort therapy.2 

This article will explore the long-term outcomes of heart transplants in patients with severe cardiomegaly, examining survival rates, quality of life, complications, and strategies for improving outcomes.

Understanding severe cardiomegaly

Cardiomegaly involves the enlargement of the heart’s ventricles or atria. Initially, this is a compensatory mechanism by which the heart’s muscles are remodelled to work harder to meet the body’s demands. However, over time, this heart remodelling causes the heart muscle to stretch or thin, impairing its ability to contract and leading to decreased cardiac output.

As a result, cardiomegaly can lead to heart failure, a condition in which the heart can still supply enough blood for organs to function at rest, but struggles to meet the body’s increased demands during exercise. Symptoms of both cardiomegaly and progressive heart failure include:

Since heart transplantation is considered a therapy of last resort for patients with cardiomegaly, it is only pursued after other treatments have been attempted, such as beta-blockers and ACE inhibitors, which are well-established therapies for reducing cardiomegaly.²

Survival and quality of life post-transplant

A vital aspect of heart transplantation is early referral to the transplant list, emphasising the importance of recognising the symptoms of heart failure and cardiomegaly. This ensures that patients can survive on medication or mechanical support until a donor heart becomes available. Clear guidelines and effective methods for identifying and treating rejection of the donor heart have led to mostly positive outcomes following transplantation.

According to the International Society of Heart and Lung Transplantation, the one-year survival rate is 84.5%, and the five-year survival rate is 72.5%. This represents a significant improvement since the 1980s, when the five-year survival was approximately 62.7%. The development of immunosuppressive drugs, which prevent the recipient’s immune system from attacking the donor heart, has contributed greatly to this success. 

The 20-year survival rates vary but overall remain promising, with the University Hospital Zurich reporting a 55.6% survival rate, compared with an international registry report of 21%.3 In the UK, the average survival after a heart transplant is 14 years.

Patients generally experience a longer lifespan and can return to a near-normal life. As the donor heart is stronger and more efficient at meeting the body’s oxygen demands, patients typically feel more energetic and can exercise properly. Post-transplant, patients are advised to adopt a healthier lifestyle, including a well-rounded diet and avoiding excessive sugar, salt, and saturated fats.

Common complications and challenges

The first few months after the heart transplant are when the patient is at their highest risk of acute rejection, the leading cause of death after the procedure. This is when the recipient’s immune system attacks the transplanted heart because it is ‘foreign’.

Rejection can be acute, when rejection occurs within the first year of the transplant, or chronic rejection, which develops over a longer period. Recipients must be aware of symptoms associated with post-transplant rejection, such as:4

  • Fatigue
  • Shortness of breath
  • Arrhythmia
  • Dizziness 

These symptoms are similar to those of cardiomegaly and progressive heart failure, which emphasises the importance of alerting your doctor as soon as possible. This way, an improved immunosuppressive therapy or close monitoring can help manage this problem. 

In addition, the most common long-term risks, which over 10% of patients may experience, include:

Future directions in heart transplantation for cardiomegaly

Future research is primarily focused on enhancing immunosuppressive therapy, given that acute rejection remains the leading cause of death post-transplant. The advent of newer immunosuppressive drugs and more durable mechanical circulatory support (MCS) devices offers hope for improving outcomes. MCS can serve as a long-term solution for heart failure if a suitable donor heart is unavailable, although this therapy is associated with complications such as infections, strokes, and thrombosis. 

Furthermore, MCS devices place a financial strain on healthcare systems, reinforcing the need for continued research into medications that can alleviate cardiomegaly. Improved understanding of transplant rejection could also pave the way for more patients personalised post-transplant monitoring.5

Another intriguing prospect for addressing donor shortages is xenotransplantation. Pig hearts are particularly promising candidates, as they are similar in size and anatomy to human hearts. In non-human models, pig heart transplants have so far been limited by primary graft dysfunction, rather than immune rejection, with survival reaching up to 57 days.

A further limitation is the risk of infection by porcine endogenous retroviruses, which could infect myocardial cells following xenotransplantation. The weight of research required to enhance this method of transplantation is substantial, which makes its research less attractive.5

Summary

Cardiomegaly initially represents a compensatory mechanism, enabling the heart to remodel and become larger and more muscular to meet the body’s oxygen demands. However, over time, the heart becomes stiff and its ability to pump blood is impaired. This ultimately leads to heart failure, a condition where the heart can no longer adequately circulate blood around the body. Patients with heart failure or cardiomegaly typically present with symptoms such as fatigue, chest pain, arrhythmia, and shortness of breath.

Heart transplantation is considered a last-resort therapy for patients who do not respond to medications such as beta-blockers or ACE inhibitors, which are designed to alleviate cardiomegaly. Overall, heart transplants provide favourable outcomes for post-operative quality of life and can extend a patient’s lifespan by over 20 years.

Current research aims to address acute rejection, the most common cause of death in post-transplant patients. Although mechanical circulatory support devices offer an alternative for some patients, they are associated with complications. In the future, xenotransplantation may become a viable solution to the shortage of donor hearts, owing to the anatomical similarities between pig and human hearts.

References

  1. Truszkiewicz K, Poręba R, Gać P. Radiological cardiothoracic ratio in evidence-based medicine. Journal of Clinical Medicine [Internet]. 2021 May 8 [cited 2024 Nov 15];10(9):2016. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8125954/ 
  2. Amin H, Siddiqui WJ. Cardiomegaly. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Nov 15]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK542296/ 
  3. Wilhelm MJ. Long-term outcome following heart transplantation: current perspective. Journal of Thoracic Disease [Internet]. 2015 Mar [cited 2024 Nov 15];7(3):549. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4387387/ 
  4. Ludhwani D, Abraham J, Sharma S, Kanmanthareddy A. Heart transplantation rejection. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Nov 15]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537057/ 
  5. Koomalsingh K, Kobashigawa JA. The future of cardiac transplantation. Annals of Cardiothoracic Surgery [Internet]. 2018 Jan [cited 2024 Nov 15];7(1):135. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5827123/ 

Share

Michael Collins

Master of Science - MS, Oncology, University of Nottingham

arrow-right